Get the Daily Brief
Latest Biotech News
Hermes Biosciences raises $6M seed — automating extracellular vesicle isolation
Hermes Biosciences closed a $6 million seed round led by Genoa Ventures to commercialize a benchtop, hands‑off extracellular vesicle (EV) isolation system aimed at research and clinical labs. The...
Nvidia, Sheba, Mount Sinai team to build genomic LLM — noncoding DNA in focus
Nvidia, Sheba Medical Center’s ARC Innovation, and the Icahn School of Medicine at Mount Sinai launched a three‑year collaboration to develop a genomic foundation model (gFM) — a large language...
Fecal exfoliome (Foli‑seq) validated — new noninvasive window into gut immune state
Columbia University researchers introduced exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host RNAs from exfoliated gut cells in feces to monitor intestinal and immune...
Solid licenses AAV‑SLB101 to Andelyn — next‑gen capsid expands CDMO offerings
Solid Biosciences granted Andelyn Biosciences a non‑exclusive worldwide license to use AAV‑SLB101, Solid’s next‑generation capsid engineered for enhanced skeletal muscle and cardiac tropism with...
FDA tightens Elevidys label: myocarditis warnings and use limits
The FDA updated the prescribing information for Sarepta Therapeutics’ gene therapy Elevidys (for Duchenne muscular dystrophy), adding stronger myocarditis language and troponin‑I monitoring...
J&J pays $3.05B for Halda: buys RIPTAC 'hold-and-kill' platform
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD‑0915 for...
Merck snaps up Cidara for $9.2B: targets long‑acting influenza prevention
Merck agreed to acquire Cidara Therapeutics for $9.2 billion to add CD388, a long‑acting, strain‑agnostic antiviral currently in Phase III (ANCHOR) for influenza prevention in high‑risk...
Zanidatamab beats trastuzumab: Phase III HERIZON‑GEA‑01 posts positive topline data
Partners Zymeworks, Jazz Pharmaceuticals and BeOne Medicines announced positive topline results from the Phase III HERIZON‑GEA‑01 trial: zanidatamab (Ziihera) plus chemotherapy improved...
Roche's oral SERD clears planned interim: adjuvant breast cancer hit
Roche reported a planned interim success in a Phase III adjuvant trial of its oral selective estrogen receptor degrader, giredestrant, showing the agent reduced early recurrence when given after...
NIH grant cuts halt 383 trials — 74,311 participants left in limbo
A Harvard‑led analysis published in JAMA Internal Medicine found NIH funding cuts from late February to mid‑August led to termination of 383 trials, affecting more than 74,000 enrolled...
Iambic raises $100M to move AI‑discovered oncology candidates toward clinic
Iambic secured $100 million to advance AI‑discovered oncology drugs into clinical testing, following presentation of data for a breast cancer candidate at a recent oncology conference. The...
Solve Therapeutics pulls in $120M: targets best‑in‑class ADCs
Solve Therapeutics closed a $120 million financing round to develop next‑generation antibody‑drug conjugates, including novel linker technologies the company says can improve therapeutic index and...
Rapid sepsis test matches blood culture: Ocean Dx hits 100% sensitivity & specificity
Ocean Dx reported a clinical evaluation in which its rapid sepsis assay matched the gold‑standard reference, returning 100% sensitivity and 100% specificity against blood cultures while...
Foli‑seq captures the 'exfoliome': noninvasive fecal RNA tool maps gut immune states
Researchers introduced exfoliome sequencing (Foli‑seq) — a targeted, multiplexed amplicon approach that profiles host mRNA from exfoliated gut cells in feces — and demonstrated the method can...
Neural stem cell transplant restores primate forelimb function — major translational step
A Nature Biotechnology study reported that transplanting human embryonic stem cell‑derived spinal cord neural stem cells (H9‑scNSCs) into injured rhesus monkeys restored forelimb and hand function...
J&J buys Halda for $3.05B: acquires RIPTAC platform and lead prostate drug
Johnson & Johnson agreed to acquire Halda Therapeutics for $3.05 billion in cash, securing Halda’s regulated induced proximity targeting chimera (RIPTAC) platform and lead candidate HLD-0915....
Ziihera Phase 3: zanidatamab shows PFS and OS gains in first-line GEA
Zymeworks and partners Jazz Pharmaceuticals and BeOne announced positive topline results from the Phase 3 HERIZON‑GEA‑01 trial testing zanidatamab (Ziihera) with chemotherapy, with and without...
Stem cell transplant restores primate hand function: path to clinical translation
Two Nature Biotechnology reports revealed that transplanting human embryonic stem cell‑derived spinal cord neural stem cells restored forelimb/hand function in nonhuman primates with cervical...
Foli‑seq: fecal exfoliome sequencing maps gut immune and epithelial states
Researchers at Columbia University unveiled exfoliome sequencing (Foli‑seq), a targeted amplicon approach that profiles host mRNA from exfoliated gut cells in feces to monitor intestinal and...
Roche previews Axelios 1: fast SBX sequencing shows cancer‑genomics promise
Roche and early users presented early data for the Axelios 1 sequencing‑by‑expansion (SBX) nanopore platform at AMP, positioning the instrument for rapid cancer genomics and ctDNA analysis....